Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
45.55 CHF | +0.77% | -5.20% | +6.55% |
Feb. 16 | BB Biotech's Loss Narrows in FY23; Operating Income Down | MT |
Feb. 14 | BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 32.1M 35.58M | Sales 2025 * | 100M 111M | Capitalization | 2.5B 2.77B |
---|---|---|---|---|---|
Net income 2024 * | 25M 27.71M | Net income 2025 * | 72M 79.81M | EV / Sales 2024 * | 88.8 x |
Net Debt 2024 * | 354M 392M | Net Debt 2025 * | 362M 402M | EV / Sales 2025 * | 28.6 x |
P/E ratio 2024 * |
91.1
x | P/E ratio 2025 * |
15.3
x | Employees | 10 |
Yield 2024 * |
5.4% | Yield 2025 * |
5.4% | Free-Float | 97.24% |
1 day | +0.77% | ||
1 week | -5.20% | ||
Current month | -0.55% | ||
1 month | -2.25% | ||
3 months | +7.81% | ||
6 months | +10.29% | ||
Current year | +6.55% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Koller
CIO | Chief Investment Officer | 54 | 03-12-31 |
- | - | ||
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Clive Meanwell
BRD | Director/Board Member | 67 | 03-12-31 |
Director/Board Member | 63 | 19-12-31 | |
Chairman | 63 | 19-03-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 45.55 | +0.77% | 58,550 |
24-03-27 | 45.2 | -0.33% | 58,003 |
24-03-26 | 45.35 | +0.33% | 43,788 |
24-03-25 | 45.2 | -4.03% | 104,870 |
24-03-22 | 47.1 | -1.98% | 64,047 |
Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.55% | 2.77B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |